Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2-Reference-Cited by-同舟云学术

Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2

Published:2013-10 Issue:1 Volume:67 Page:89-97
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Gould Janet C.,Kasichayanula Sreeneeranj,Shepperly David C.,Boulton David W.

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference24 articles.

1. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial;Bailey;Lancet,2010

2. Improvements in quantitative noncancer risk assessment. Sponsored by the risk assessment specialty section of the society of toxicology;Beck;Fundamental and Applied Toxicology: Official Journal of the Society of Toxicology,1993

3. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting;Calado;Kidney International,2006

4. EPA, 2002. Environmental protection agency. A review of the reference dose and reference concentration processes. EPA/600/P-02/002F. Available from: (accessed 29.09.12).

5. EPA, 2011. Environmental protection agency. Exposure factors handbook EPA/600/R-090/052F, Available from: (accessed 29.09.12).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus;British Journal of Clinical Pharmacology;2023-11-20

2. Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus;The Journal of Clinical Pharmacology;2023-01-12

3. Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus;The Journal of Clinical Pharmacology;2022-05-02

4. Toxicokinetic and toxicodynamic considerations when deriving health-based exposure limits for pharmaceuticals;Regulatory Toxicology and Pharmacology;2016-08

5. Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs);Regulatory Toxicology and Pharmacology;2016-08